C Bantar

Summary

Country: Argentina

Publications

  1. ncbi request reprint A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance
    Carlos Bantar
    Committee for Prevention and Control of Nosocomial Infection, Hospital San Martin, Parana, Entre Rios, Argentina
    Clin Infect Dis 37:180-6. 2003
  2. doi request reprint [Updated acute community-acquired pneumonia in adults: Guidelines for initial antimicrobial therapy based on local evidence from the South American Working Group (ConsenSur II)]
    Carlos Bantar
    Hospital San Martin, Parana, Argentina
    Rev Chilena Infectol 27:S9-S38. 2010
  3. ncbi request reprint Intravenous amoxicillin-sulbactam against Escherichia coli: optimizing the dose, component ratio and infusion time using a human pharmacodynamic model
    C Bantar
    Laboratorio Domingo I Nanni Paraná, Hospital Aleman, Buenos Aires, Argentina
    J Chemother 21:296-301. 2009
  4. ncbi request reprint Comparative in vitro activity of tigecycline against bacteria recovered from clinical specimens in Latin America
    C Bantar
    Hospital San Martin, Parana, Argentina
    J Chemother 21:144-52. 2009
  5. ncbi request reprint Comparative time-kill study of doxycycline, tigecycline, sulbactam, and imipenem against several clones of Acinetobacter baumannii
    Carlos Bantar
    Laboratorio Domingo I Nanni, Parana, Entre Rios, Argentina
    Diagn Microbiol Infect Dis 61:309-14. 2008
  6. ncbi request reprint An ex-vivo pharmacodynamic study comparing bactericidal activity of amoxicillin/sulbactam, azithromycin, doxycycline and levofloxacin against Streptococcus pneumoniae
    C Bantar
    Laboratorio Domingo I Nanni Paraná, Argentina
    J Chemother 16:248-54. 2004
  7. ncbi request reprint Alternative indicators for monitoring the quality of a continuous intervention program on antibiotic prescribing during changing healthcare conditions
    C Bantar
    Services of Infection Control, Hospital San Martin, Parana, Entre Rios, Argentina
    J Chemother 17:277-82. 2005
  8. ncbi request reprint Does a reduction in antibiotic consumption always represent a favorable outcome from an intervention program on prescribing practice?
    Carlos Bantar
    Services of Infection Control, Hospital San Martin, Parana, Entre Rios, Argentina
    Int J Infect Dis 10:231-5. 2006
  9. ncbi request reprint Are laboratory-based antibiograms reliable to guide the selection of empirical antimicrobial treatment in patients with hospital-acquired infections?
    Carlos Bantar
    Department of Infection Control, Hospital San Martin, Perón 450 3100 Paraná, Entre Rios, Argentina
    J Antimicrob Chemother 59:140-3. 2007
  10. ncbi request reprint Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (ConsenSur)
    C Bantar
    Hospital San Martin, Parana, Argentina
    J Chemother 14:1-22. 2002

Detail Information

Publications29

  1. ncbi request reprint A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance
    Carlos Bantar
    Committee for Prevention and Control of Nosocomial Infection, Hospital San Martin, Parana, Entre Rios, Argentina
    Clin Infect Dis 37:180-6. 2003
    ..The present study indicates that a systematic program performed by a multidisciplinary team is a cost-effective strategy for optimizing antibiotic prescribing...
  2. doi request reprint [Updated acute community-acquired pneumonia in adults: Guidelines for initial antimicrobial therapy based on local evidence from the South American Working Group (ConsenSur II)]
    Carlos Bantar
    Hospital San Martin, Parana, Argentina
    Rev Chilena Infectol 27:S9-S38. 2010
    ..Like in the first versión of the ConsenSur (ConsenSur I), the various current guidelines have helped to organize and stratify the present proposal, ConsenSur II...
  3. ncbi request reprint Intravenous amoxicillin-sulbactam against Escherichia coli: optimizing the dose, component ratio and infusion time using a human pharmacodynamic model
    C Bantar
    Laboratorio Domingo I Nanni Paraná, Hospital Aleman, Buenos Aires, Argentina
    J Chemother 21:296-301. 2009
    ..5g combination. These findings encourage the performance of clinical trials to assess the efficacy of this combination, given as an extended infusion, in the treatment of community-acquired intra-abdominal infections...
  4. ncbi request reprint Comparative in vitro activity of tigecycline against bacteria recovered from clinical specimens in Latin America
    C Bantar
    Hospital San Martin, Parana, Argentina
    J Chemother 21:144-52. 2009
    ..Results from the present study suggest that tigecycline may be a suitable option in latin America, a region where multidrug resistance seems to be a dramatic, increasing problem and new antimicrobial choices are urgently needed...
  5. ncbi request reprint Comparative time-kill study of doxycycline, tigecycline, sulbactam, and imipenem against several clones of Acinetobacter baumannii
    Carlos Bantar
    Laboratorio Domingo I Nanni, Parana, Entre Rios, Argentina
    Diagn Microbiol Infect Dis 61:309-14. 2008
    ..baumannii, suggests that doxycycline could be a suitable, cost-effective, alternative option in some instances, and sheds light on the potential role of tigecycline in the treatment of infections with this organism...
  6. ncbi request reprint An ex-vivo pharmacodynamic study comparing bactericidal activity of amoxicillin/sulbactam, azithromycin, doxycycline and levofloxacin against Streptococcus pneumoniae
    C Bantar
    Laboratorio Domingo I Nanni Paraná, Argentina
    J Chemother 16:248-54. 2004
    ..It also provides the basis for a "warning signal" on the use of oral DOX and confirms the efficacy of AMX-SUL...
  7. ncbi request reprint Alternative indicators for monitoring the quality of a continuous intervention program on antibiotic prescribing during changing healthcare conditions
    C Bantar
    Services of Infection Control, Hospital San Martin, Parana, Entre Rios, Argentina
    J Chemother 17:277-82. 2005
    ....
  8. ncbi request reprint Does a reduction in antibiotic consumption always represent a favorable outcome from an intervention program on prescribing practice?
    Carlos Bantar
    Services of Infection Control, Hospital San Martin, Parana, Entre Rios, Argentina
    Int J Infect Dis 10:231-5. 2006
    ..Therefore, we hypothesized that the consumption of these drugs could be a suitable indirect marker of the crisis...
  9. ncbi request reprint Are laboratory-based antibiograms reliable to guide the selection of empirical antimicrobial treatment in patients with hospital-acquired infections?
    Carlos Bantar
    Department of Infection Control, Hospital San Martin, Perón 450 3100 Paraná, Entre Rios, Argentina
    J Antimicrob Chemother 59:140-3. 2007
    ..In this study, we performed a paired comparison between the antibiogram constructed with laboratory-based data and that formed with data subjected to prior clinical validation...
  10. ncbi request reprint Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (ConsenSur)
    C Bantar
    Hospital San Martin, Parana, Argentina
    J Chemother 14:1-22. 2002
    ....
  11. ncbi request reprint Impact of antibiotic treatment on bacterial resistance rates from patients with hospital-acquired infection
    C Bantar
    Department of Infection Control, Hospital San Martin, Entre Rios, Argentina
    J Chemother 19:673-6. 2007
    ....
  12. doi request reprint Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model
    Carlos Bantar
    Laboratorio Domingo I Nanni, Entre Rios, PR, Argentina
    Braz J Infect Dis 13:348-52. 2009
    ..A 2-g sulbactam dose seems to be optimal to be infused over 30 min with a 6-h dosing interval. When infused over 3h, AMX-SUL 1g/1g given every 6h or 8h seems a suitable dosing schedule...
  13. ncbi request reprint Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms
    C Bantar
    Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina
    J Chemother 13:402-6. 2001
    ..influenzae or penicillin-resistant (MIC > or =2 microg/ml) S. pneumoniae isolates. Either shorter dosing intervals (t.i.d.) or a higher amoxicillin content in the formulation (i.e. 875 mg) may be required in these situations...
  14. ncbi request reprint A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections
    C Bantar
    Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina
    J Chemother 12:223-7. 2000
    ..The AMX-SUL formulation evaluated in this study showed pharmacodynamic features that support clinical trials to assess its efficacy in the treatment of lower respiratory tract infections with a 12-h dosing interval regimen...
  15. ncbi request reprint Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia: a clinical trial based on a pharmacodynamic model
    A Jasovich
    Hospital Bocalandro, Buenos Aires, Argentina
    J Chemother 14:591-6. 2002
    ..i.d. regimen...
  16. ncbi request reprint A 7-year national survey on bacterial resistance in bronchoalveolar lavage from patients hospitalized in Argentina
    Carlos Bantar
    Sociedad Argentina de Bacteriología, Asociación Argentina de Microbiología, Buenos Aires, Argentina
    Diagn Microbiol Infect Dis 60:65-9. 2008
    ..Variations over time support the need for systematic tailored surveillance and compel us to establish a rational usage of antimicrobial agents in our country...
  17. ncbi request reprint Review of pharmacokinetic, pharmacodynamic and clinical studies with a modern combination of amoxicillin/sulbactam
    J Soutric
    Medical Department, Laboratorios Bagó SA Argentina, Buenos Aires, Argentina
    Chemotherapy 52:200-4. 2006
    ..In this review we present the most relevant pharmacokinetic, pharmacodynamic and clinical information associated with its use...
  18. ncbi request reprint Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains
    C Bantar
    Department of Microbiology, Centro de Educación Médica e Investigaciones Clínicas Dr Norberto Quirno, Billingurst 2447, 1425, Buenos Aires, Argentina
    Diagn Microbiol Infect Dis 37:41-4. 2000
    ..The higher in vitro activity of cefepime over that of ceftazidime against imipenem-resistant P. aeruginosa strains highlights the differences of these drugs beyond Enterobacterspp. and Staphylococcus aureus...
  19. pmc Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination, against Escherichia coli
    C Bantar
    Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina
    Antimicrob Agents Chemother 43:1503-4. 1999
    ..Peak serum bactericidal and urine inhibitory activities in most volunteers were observed against E. coli strains for which AMX-SUL MICs were low (2- to 4-mg/liter) (2 strains) and high (>/=16-mg/liter) (47 strains), respectively...
  20. ncbi request reprint Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection
    J Smayevsky
    C E M I C, Buenos Aires, Argentina
    Diagn Microbiol Infect Dis 37:261-4. 2000
    ..aureus were lower than those of levofloxacin and ciprofloxacin.Therefore, this new fluoroquinolone displayed in vitro features that make it suitable for treating community-acquired respiratory tract infections...
  21. pmc Species belonging to the "Streptococcus milleri" group: antimicrobial susceptibility and comparative prevalence in significant clinical specimens
    C Bantar
    Department of Microbiology, Centro de Education Medica e Investigaciones Clinicas, Buenos Aires, Argentina
    J Clin Microbiol 34:2020-2. 1996
    ....
  22. ncbi request reprint Comparative in vitro activity of tigecycline against aerobic and facultative isolates recovered from hospitalized patients: an Argentinean multicenter study
    J M Casellas
    Microbiology Department of Centro de Estudios en Antimicrobianos, San Isidro, Buenos Aires, Argentina
    J Chemother 19:482-7. 2007
    ..25/1); S. agalactiae 51 (0.5/0.5); Enterococcus spp. 104 (0.06/0.12); Pseudomonas aeruginosa 169 (8/16). We conclude that tigecycline is a promising drug for the treatment of infections in hospitalized patients in Argentina...
  23. ncbi request reprint Efficacy and pharmacodynamics of teicoplanin given daily during the first 3 days and then on alternate days for methicillin-resistant Staphylococcus aureus infections
    C Bantar
    Department of Microbiology and Infectious Diseases of the Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina
    J Antimicrob Chemother 43:737-40. 1999
    ..The mean serum levels of teicoplanin (mg/L) were 22, 8 and 6.7 for peak, 24 h and 48 h troughs, respectively. The dosage employed in this study proved effective in non-deep-seated MRSA infections...
  24. ncbi request reprint [Consensus on antimicrobial sensitivity tests in gram-positive cocci. Subcommittee on Antimicrobials, SADEBAC (Argentinian Society of Clinical Bacteriology), Argentinian Association of Microbiology]
    A Famiglietti
    Subcomisión de Antimicrobianos, SADEBAC, AAM, Bulnes 44 PB B, 1176, Buenos Aires, Argentina
    Rev Argent Microbiol 35:29-40. 2003
    ....
  25. ncbi request reprint [Diarrhea due to microsporidia in a patient with AIDS]
    C Bantar
    Laboratorio de Microbiologia, Clínicas Dr Norberto Quirno CEMIC, Buenos Aires, Argentina
    Medicina (B Aires) 55:685-8. 1995
    ..To our knowledge, this is the first microsporidial infection reported in Argentina...
  26. pmc Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance
    Carlos Bantar
    Committee for Prevention and Control of Nosocomial Infection, Hospital San Martin, Parana, Entre Rios, Argentina
    Antimicrob Agents Chemother 48:392-5. 2004
    ..pneumoniae and P. mirabilis, even where there are high bacterial resistance rates and irrespective of any additional precautions for controlling nosocomial infection...
  27. ncbi request reprint Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients
    Jose Maria Casellas
    Centro de Estudios en Antimicrobianos CEA, Buenos Aires City Reference Center, Buenos Aires, Argentina
    Diagn Microbiol Infect Dis 47:527-37. 2003
    ..Caution must be taken for infections due to ESBL producers considering that the inoculum effect MICs can affect MIC values...
  28. ncbi request reprint Central venous catheter-related infection: a prospective, observational study to assess the incidence rate at a teaching hospital in Argentina
    Carlos Bantar
    Committee for Prevention and Control of Nosocomial Infections, Hospital San Martin, Parana, Entre Rios, Argentina
    Infect Control Hosp Epidemiol 23:757-8. 2002
    ..The infection rate was higher for CVCs with a duration of less than 6 days than for those with a longer duration. Our data suggest that scheduled replacement of CVCs is not necessary...
  29. ncbi request reprint How much evidence do we have to recommend oral doxycycline for empirical treatment of community-acquired pneumonia?
    Carlos Bantar
    Clin Infect Dis 38:459-60. 2004